Treatments New Drug Results with CAL101 for Lymphoma Patients
Dr. Brad Kahl at the UW Carbone Cancer Center discusses a new drug for lymphoma patients called CAL101. Patients on this medication feel no ill effect of taking this pill, and of the first 6 people to whom Dr. Kahl has given this agent to, all 6 of them have experienced some clinical benefit. These benefits include shrinkage of lymph nodes and tumor cells. When you look at the data all across the study from the other sites, 6 out of 7 mantle cell lymphoma patients responded to this drug, over half of the follicular patients responded to this drug, and a large percentage of patients with a disease called chronic lymphocytical leukemia have responded to this drug.
Other video segments available in this category
Get More from Forward Lymphoma
Sign up to receive more information from Forward Lymphoma and the Carbone Cancer Center.
Download the Helping Lymphoma Patients with Research Focused on Psychological Recovery white paper.
Download the Determining Who is Right for Rituximab white paper.
Download the Using Stem Cells to Develop Patient Specific Treatments white paper.
